Tal Zaks - Bridging Science, Medicine, and Returns - [Invest Like the Best, EP.406] · Invest Like the Best with Patrick O'Shaughnessy summary

Key takeaways

Advancements in technology, particularly mRNA, are revolutionizing the field of medicine, yet there remain significant challenges in translating these into successful treatments.
The investment landscape in biotech requires a multidisciplinary approach while balancing science, commercial viability, and inherent unpredictability.
Effective collaboration and rapid response mechanisms were crucial during the development of COVID-19 vaccines, highlighting the importance of partnerships in healthcare.
The future of healthcare may see a shift towards personalized medicine through mRNA and gene therapies, raising important ethical considerations.
AI holds strong potential for improving healthcare but must be carefully integrated to balance its efficiency and the preservation of patient autonomy.

Summary

The State of Modern Medicine

Tal Zaks discusses the current state of medicine, emphasizing the significant advancements in technology and treatments. He expresses optimism about the progress in life sciences, particularly in areas like mRNA technology and the potential for personalized medicine. However, he also notes the persistent challenges in translating scientific breakthroughs into effective treatments due to the unpredictability of biology.

Investment in Biotech: Challenges and Process

Zaks outlines the complexities of investing in biotech, recognizing the crucial balance of science, commercial viability, and the unpredictability of clinical outcomes. He shares insights into the investment process, including the importance of a strong team, understanding the underlying science, and identifying the next value inflection points. He highlights the differences in mindset required between investors and company executives.

Insights from COVID-19 Vaccine Development

Drawing from his experience as Chief Medical Officer at Moderna, Zaks recounts the rapid development of the COVID-19 vaccine, crediting a well-prepared platform and effective collaboration with government entities. He emphasizes the unparalleled safety measures taken and the vast amount of data collected, which set new standards for vaccine safety in history versus public perception and trust in health institutions.

The Future of mRNA and Nucleic Acid Medicines

Zaks discusses the exciting potential of mRNA and other nucleic acid medicine technologies, arguing that these platforms can fundamentally change the landscape of healthcare. By enabling targeted treatments for individual genetic profiles, these innovations could lead to cures for diseases that currently have none. But he acknowledges the ethical challenges and public concerns that come with these advancements.

The Role of AI in Healthcare

Exploring the implications of artificial intelligence in medicine, Zaks presents a bifurcated view of its potential. The bear case entails slow, piecemeal advancements, while the bullish view predicts a transformation in productivity if integration occurs effectively. He stresses the need to prioritize patient ethical considerations alongside technological progress, advocating that the integration of AI should enhance rather than diminish human oversight in healthcare.

Show notes

My guest today is Tal Zaks. Tal is a physician-scientist turned biotech executive and investor who served as Moderna's Chief Medical Officer during their COVID-19 vaccine development, giving him an extraordinary perspective on one of modern medicine's pivotal moments. His combination of medical expertise, platform innovation experience, and investing acumen allows us to explore the interconnected challenges of turning scientific breakthroughs into viable medicines while generating venture-scale returns. We dive deep into lessons from Moderna's mRNA platform, examine how emerging technologies might reshape drug development, and the fundamental question of what it means to make people healthier. For investors, entrepreneurs, and anyone interested in the future of medicine, this discussion provides a window into both the immense potential and profound challenges of advancing human health. Please enjoy my conversation with Tal Zaks.

For the full show notes, transcript, and links to mentioned content, check out the episode page here.
-----
This episode is brought to you by Ramp. Ramp’s mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Ramp is the fastest-growing FinTech company in history, and it’s backed by more of my favorite past guests (at least 16 of them!) than probably any other company I’m aware of. Go to Ramp.com/invest to sign up for free and get a $250 welcome bonus.
–
This episode is brought to you by AlphaSense. AlphaSense has completely transformed the research process with cutting-edge AI technology and a vast collection of top-tier, reliable business content. Imagine completing your research five to ten times faster with search that delivers the most relevant results, helping you make high-conviction decisions with confidence. Invest Like the Best listeners can get a free trial now at Alpha-Sense.com/Invest and experience firsthand how AlphaSense and Tegus help you make smarter decisions faster.
–
This episode is brought to you by Ridgeline. Ridgeline has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. I think this platform will become the standard for investment managers, and if you run an investing firm, I highly recommend you find time to speak with them. Head to ridgelineapps.com to learn more about the platform.
-----
Invest Like the Best is a property of Colossus, LLC. For more episodes of Invest Like the Best, visit joincolossus.com/episodes.
Follow us on Twitter: @patrick_oshag | @JoinColossus
Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).
Show Notes:
(00:00:00) Welcome to Invest Like the Best
(00:08:37) State of Medicine Today
(00:09:44) Investment and Innovation in Medicine
(00:13:14) Challenges in Biotech Investment
(00:17:18) Personalized Cancer Vaccines
(00:22:58) Investing in Biotech: Process and Considerations
(00:28:38) Multidisciplinary Approach in Pharma
(00:41:35) COVID-19 Vaccine Development
(00:46:27) Funding and Manufacturing Challenges
(00:48:01) Unprecedented Vaccine Safety Measures
(00:50:38) Public Perception and Trust Issues
(00:53:54) Future of mRNA and Nucleic Acid Medicines
(00:58:04) Personalized Medicine and Data Collection
(01:04:48) AI's Role in Healthcare
(01:08:34) Investment Strategies in Therapeutics
(01:14:57) The Human Element in Medical Innovation
(01:21:58) The Kindest Thing Anyone Has Ever Done for Tal

Tal Zaks - Bridging Science, Medicine, and Returns - [Invest Like the Best, EP.406]